Merck KGaA, Taiho deal

MRK acquired global rights to colorectal cancer drug UFT tegafur/uracil from Taiho. The deal excludes Japan, South Korea, Taiwan, Malaysia and Singapore. Earlier this month, Bristol-Myers Squibb Co. (BMY, New York, N.Y.) returned its rights to the drug to Taiho to focus on its late-stage oncology pipeline. ...